NIH, FDA Announcements Aim to Bolster Animal Alternatives

Key Points

• The aim is to promote the use of non-animal alternatives in research, particularly concerning drug development.
• FDA issued guidance on evaluating non-animal alternatives for pharmacology and toxicology.
• NIH allocated over $150 million for the development of additional non-animal methodologies.
• Collaboration with cancer researchers to assess the readiness of alternatives.
• FDA's guidance marks the first of its kind for non-animal drug evaluation.
• NIH funding will support multiple centers focused on new approach methodologies.
• Cancer researchers express that existing alternatives are not yet sufficient to fully replace animal models.

Abstract